ReviewTrends in cardiovascular medicine2016
Recent progress in understanding the natural and clinical histories of the Marfan syndrome.
Review in Trends in cardiovascular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 61 citations in OpenAlex.
- Assessment of Hip Joint Articular Cartilage Composition in People with Marfan Syndrome Utilizing T1ρ and T2 Mapping.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026Article
- Connective tissue disorder and high risk pregnancy: a case series with personalised external aortic root support (PEARS).Nature communications · 2025Article
- Assessing hip joint-related structure and patient-reported outcomes in people with Marfan syndrome.Skeletal radiology · 2025Article
- Differential Oral Microbiota and Serum Cytokine Signatures in Age-Grouped Patients with Marfan Syndrome.Biomedicines · 2025Article
- The Contribution of Mast Cells to the Regulation of Elastic Fiber Tensometry in the Skin Dermis of Children with Marfan Syndrome.International journal of molecular sciences · 2024Article
- Skin mast cells in Marfan syndrome: specific emphasis on connective tissue remodeling.Archives of dermatological research · 2024Article
- Ocular, cardiovascular, and genetic characteristics and their associations in children with Marfan syndrome and related fibrillinopathies.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Article
- Current Understanding of Aortic Dissection.Life (Basel, Switzerland) · 2022Review
- Tracking an Elusive Killer: State of the Art of Molecular-Genetic Knowledge and Laboratory Role in Diagnosis and Risk Stratification of Thoracic Aortic Aneurysm and Dissection.Diagnostics (Basel, Switzerland) · 2022Review
- Identification of pathological-related and diagnostic potential circular RNAs in Stanford type A aortic dissection.Frontiers in cardiovascular medicine · 2022Article
- Functional Analysis of an Intronic FBN1 Pathogenic Gene Variant in a Family With Marfan Syndrome.Frontiers in genetics · 2022Article
- Increased Risk of Aortic Dissection with Perlecan Deficiency.International journal of molecular sciences · 2021Article
- Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52.International journal of molecular sciences · 2021Article
- Pathophysiology and Pathogenesis of Marfan Syndrome.Advances in experimental medicine and biology · 2021Review
- Efficacy of cardiovascular surgery for Marfan syndrome patients: a single-center 15-year follow-up study.Journal of thoracic disease · 2020Article
- Effects of fibrillin mutations on the behavior of heart muscle cells in Marfan syndrome.Scientific reports · 2020Article
- Marfan syndrome: improved clinical history results in expanded natural history.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Review
- Marfan syndrome; A connective tissue disease at the crossroads of mechanotransduction, TGFβ signaling and cell stemness.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Imaging of the Postsurgical Aorta in Marfan Syndrome.Current treatment options in cardiovascular medicine · 2018Review
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 4 decades, remarkable progress in understanding the cause, pathogenesis, and management of the MFS has led to an increase in life expectancy to near normal for most patients. Accompanying this increased life span has been the emergence of previously rare or unanticipated clinical problems. Despite much more detailed knowledge of the molecular, cellular, and tissue effects of a mutation in FBN1, targeted, effective therapy remains elusive. Until such precision medicine takes hold, management will depend on early diagnosis, regular scrutiny by imaging, chronic β-blockade, and perhaps ARBs, and prophylactic cardiothoracic surgery. Without question, MFS will remain a fertile subject for basic, translational, and clinical research for the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.